Full TitleA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (A021806) (CIRB)
The usual treatment for operable pancreatic cancer is to give chemotherapy after surgery. In this study, researchers want to compare this approach to a different regimen: one where patients receive chemotherapy followed by surgery and more chemotherapy. They hope giving chemotherapy both before and after surgery is more effective for preventing pancreatic cancer from coming back.
Patients in this study will be randomly assigned to receive the drug combination FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) either after surgery or both before and after surgery. These medications are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have previously untreated pancreatic cancer that will be surgically removed.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Anna Varghese at 646-497-9053.